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Abstract: The identification of biomarkers for early diagnosis of Parkinson’s disease (PD) is of
pivotal importance for improving approaches for clinical intervention. The use of translatable animal
models of pre-motor PD therefore offers optimal opportunities for novel biomarker discovery in vivo.
Peptidylarginine deiminases (PADs) are a family of calcium-activated enzymes that contribute to
protein misfolding through post-translational deimination of arginine to citrulline. Furthermore,
PADs are an active regulator of extracellular vesicle (EV) release. Both protein deimination and
extracellular vesicles (EVs) are gaining increased attention in relation to neurodegenerative diseases,
including in PD, while roles in pre-motor PD have yet to be investigated. The current study aimed at
identifying protein candidates of deimination in plasma and plasma-EVs in a rat model of pre-motor
PD, to assess putative contributions of such post-translational changes in the early stages of disease.
EV-cargo was further assessed for deiminated proteins as well as three key micro-RNAs known to
contribute to inflammation and hypoxia (miR21, miR155, and miR210) and also associated with PD.
Overall, there was a significant increase in circulating plasma EVs in the PD model compared with
sham animals and inflammatory and hypoxia related microRNAs were significantly increased in
plasma-EVs of the pre-motor PD model. A significantly higher number of protein candidates were
deiminated in the pre-motor PD model plasma and plasma-EVs, compared with those in the sham
animals. KEGG (Kyoto encyclopedia of genes and genomes) pathways identified for deiminated
proteins in the pre-motor PD model were linked to “Alzheimer’s disease”, “PD”, “Huntington’s
disease”, “prion diseases”, as well as for “oxidative phosphorylation”, “thermogenesis”, “metabolic
pathways”, “Staphylococcus aureus infection”, gap junction, “platelet activation”, “apelin signalling”,
“retrograde endocannabinoid signalling”, “systemic lupus erythematosus”, and “non-alcoholic fatty
liver disease”. Furthermore, PD brains showed significantly increased staining for total deiminated
proteins in the brain vasculature in cortex and hippocampus, as well as increased immunodetection of
deiminated histone H3 in dentate gyrus and cortex. Our findings identify EVs and post-translational
protein deimination as novel biomarkers in early pre-motor stages of PD.
Int. J. Mol. Sci. 2020, 21, 2743; doi:10.3390/ijms21082743 www.mdpi.com/journal/ijms
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1. Introduction
Identification of biomarkers for early diagnosis of Parkinson’s disease (PD) is essential for
developing early clinical intervention strategies. The use of animal models that present symptoms
comparable to those observed in PD patients in the early stages of the disease, prior to the appearance
of motor dysfunctions, therefore offers promising avenues for novel biomarker discovery in vivo.
Peptidylarginine deiminases (PADs) are a family of calcium-activated enzymes that contribute to
protein misfolding, as well as changes in protein function, through post-translational deimination
of arginine to citrulline [1,2]. Furthermore, PADs are an active regulator of extracellular vesicle
(EVs) release [3–7]. Both protein deimination and EVs are gaining increasing attention in relation to
neurodegenerative diseases [8,9], including in PD, while their roles in pre-motor PD have yet to be
investigated. Increased PAD-mediated protein deimination is indeed observed in several autoimmune,
chronic and neurodegenerative diseases, including in PD [8–14]. In PD, deiminated proteins have
been detected in substantia nigra of post-mortem human brain samples [10]. Furthermore, in PD iPSC
neuronal models, derived from fibroblasts of patients carrying α-synuclein triplication [15], an increase
and change in deiminated protein patterns has also been reported [9].
EVs are a recognized contributor to neurodegenerative diseases, and both neurotoxic and
neuroprotective roles via distribution of EV-mediated cargo, including microRNAs and misfolded
proteins, have been implicated [16,17]. In addition, EVs may be usable as a “liquid biopsy” for
identification of disease related biomarkers [8,16–20]. EVs have indeed recently been suggested as
putative biomarkers in PD [21]. For example, PD patients have been shown to have greater amounts of
circulating small EVs [22]. However, less is known about EVs in early and pre-motor stages of PD.
The current study aimed at profiling EVs and identifying protein candidates of deimination in
plasma and plasma-EVs in a rat model of pre-motor PD to determine putative contributions of such
post-translationally mediated changes in early stages of PD, including further downstream effects that
may be related to disease progression. To this end, we used a toxin-induced pre-motor PD model
that was shown to display non-motor symptoms in the absence of motor symptoms and pathologies
mimicking those observed in patients (See 4.1 in the Methods section). EV-cargo was assessed for
deiminated proteins as well as for three key microRNAs known to contribute to inflammation and
hypoxia (miR21, miR155, and miR210), all of which have also been associated to neurodegenerative
diseases and PD [23–25], but have not been related to, or assessed in, pre-motor PD before the current
study. Epigenetic mechanisms of PD have indeed received increasing attention, including histone
modifications, DNA methylation, as well as microRNA involvement [26,27]. Our findings identify EVs
and protein deimination as novel markers in pre-motor stages of PD.
2. Results
2.1. Circulating Plasma Extracellular Vesicles (EVs) are Significantly Increased in the Pre-Motor Parkinson’s
Disease (PD) Model Compared with Sham-Treated Rats
Significant changes were observed in the number of circulating plasma-EVs in the pre-motor
PD, compared with sham-treated rats, with a 2-fold increase in plasma-EVs (p = 0.031; Figure 1A).
Modal plasma-EV size did not show a significant change between the pre-motor PD and shams
(Figure 1B).
Figure 2 shows representative nanoparticle tracking analysis (NTA) profiles of EV size distribution
from shams and pre-motor PD animals (Figure 2A,B). Additional EV characterisation was carried out
by western blotting (WB) using the EV-specific markers CD63 and flotillin-1 (Flot-1), which showed
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positive for the rat EVs (Figure 2C), as well as by transmission electron microscopy (TEM), revealing
typical EV morphology (Figure 2D,E).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 3 of 36 
 
 
Figure 1. Plasma-extracellular vesicles (EVs) are elevated in pre-motor Parkinson’s disease (PD) 
model rats. (A) The number of circulating plasma-EVs was significantly increased in plasma of the 
pre-motor PD model rats, compared with that in plasma of sham control rats (p < 0.05; unpaired t-
test). (B) Modal size of plasma-EVs did not differ between plasma from the pre-motor PD rat model 
compared to control shams. Exact p-values are indicated (n = 3 biological replicates for all; ctrl=sham; 
PD=pre-motor PD models). 
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Figure 2. EV characterisation from rat plasma. (A) Representative Nanosight graphs showing 
nanoparticle tracking analysis (NTA) analysis of plasma EV profiles from sham-treated rats (Sham; n 
= 3). (B) Representative Nanosight graphs showing NTA analysis of plasma EV profiles from the pre-
motor PD rat models (PD; n = 3). (C) Western blotting (WB) confirms that rat plasma-EVs are positive 
for the EV-specific markers CD63 and flotillin-1 (Flot-1); the molecular weight standard is indicated 
in kilo Daltons (kDa). (D,E) Transmission electron microscopy (TEM) images showing EVs isolated 
from sham (D) and pre-motor PD model (PD; (E)) rat plasma, revealing typical EV morphology; 
composite images are shown and the scale bar represents 50 nm in all images. In the NTA curves the 
Figure 1. Plasma-extracellular vesicles (EVs) are elevated in pre-motor Parkinson’s disease (PD) model
rats. (A) The number of circulating plasma-EVs was significantly increased in plasma of the pre-motor
PD model rats, compared with that in plasma of sham control rats (p < 0.05; unpaired t-test). (B) Modal
size of plasma-EVs did not differ between plasma from the pre-motor PD rat model compared to control
shams. Exact p-values are indicated (n = 3 biological replicates for all; ctrl = sham; PD = pre-motor
PD models).
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Figure 2. EV characterisation from rat plasma. (A) Representative Nanosight graphs showing
nanoparticle tracking analysis (NTA) analysis of plasma EV profiles from sham-treated rats (Sham;
n = 3). (B) Representative Nanosight graphs showing NTA analysis of plasma EV profiles from the
pre-motor PD rat models (PD; n = 3). (C) Western blotting (WB) confirms that rat plasma-EVs are
positive for the EV-specific markers CD63 and flotillin-1 (Flot-1); the molecular weight standard is
indicated in kilo Daltons (kDa). (D,E) Transmission electron microscopy (TEM) images showing EVs
isolated from sham (D) and pre-motor PD model (PD; (E)) rat plasma, revealing typical EV morphology;
composite images are shown and the scale bar represents 50 nm in all images. In the NTA curves
the black line represen s the mean f the 5 repetitive readings per individu l sample and the red line
represents standard error (+/−) between those ame 5 readings per sample. Each treatment group was
measured in 3 biological replicates (sh m; PD = pre-motor PD models).
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2.2. Inflammatory and Hypoxia Related microRNA EV-Cargo is Increased in Plasma of Pre-Motor PD Models
When assessing EV-cargo for two inflammatory (miR21, miR155) and one hypoxia related
microRNA (miR210), a significant increase in relative expression was found for all three microRNAs
in plasma-EVs of the pre-motor PD models, compared with that in sham-treated animals (Figure 3).
The pro-inflammatory miR21 was increased by 7.77-fold (p = 0.00014) in pre-motor PD plasma-EVs,
compared with shams (Figure 3A); the pro-inflammatory miR155 was 11.34-fold increased (p < 0.0001)
in the pre-motor PD plasma-EVs, compared with shams (Figure 3B); and the hypoxia-related miR210
was 6.88-fold increased (p < 0.0001) in the pre-motor PD plasma-EVs, compared with shams (Figure 3C).
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animals. Results are represented as relative microRNA (miR) expression compared to the internal
control miRs (2Λ(-DDCT)); exact p-values are indicated, error bars show SD (n = 3 biological and three
technical replicates for all; ctrl = sham; PD = pre-motor PD models).
2.3. Deiminated Protein Targets and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathways Enriched in
Deiminated Proteins Differ between Pre-Motor PD and Sham-Treated Rat Plasma and Plasma-EVs
Deiminated proteins isolated by F95-enrichment were assessed by silver staining, revealing a
number of protein bands in the range of 15–200 kDa (Figure 4). There was no obvious difference
observed in protein banding patterns of F95-enriched protein eluates (F95_IP) between the sham (ctrl)
and pre-motor PD-model; neither in plasma nor plasma-EVs, while concentration of F95-enriched
proteins unexpectedly seemed slightly higher in the sham (ctrl) animals, without verifying specific
target proteins of deimination at this point. The F95-enriched eluates were further assessed by liquid
chromatography mass spectrometry (LC-MS/MS) analysis for identification of differences in deiminated
target proteins in sham, compared with pre-motor PD animals, both for plasma and plasma-EVs.
Following LC-MS/MS analysis, F95-enriched protein candidates identified were analysed for
protein–protein interaction networks using STRING (https://string-db.org/). STRING analysis revealed
some differences in Kyoto encyclopedia of genes and genomes (KEGG) pathways enriched in deiminated
proteins between the pre-motor PD model and the shams, both for plasma-EVs as well as whole
plasma. Overall, more protein hits were identified as deiminated in the pre-motor PD models, both
in EVs and whole plasma, compared with shams, with some common targets but some specific to
either shams or the pre-motor PD models as summarised in the Venn diagram in Figure 5. In summary,
118 protein hits were specific to the pre-motor PD model whole plasma and 9 deiminated protein hits
were specific to sham plasma (Figure 5A; Table 1 and Table S1). In plasma-EVs of the pre-motor PD
rats, 49 deiminated protein hits were specific, while 33 deimination hits were specific to plasma-EVs
from shams (Figure 5B, Table 2, and Table S2).
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Figure 4. F95-enriched fractions from plasma and plasma-EVs from pre-motor PD model and sham
rats. Silver stained sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel (4–20%
gradient gel), showing F95-enriched protein bands from whole plasma and plasma-EVs in pre-motor
PD and sham (control) rats. The protein standard is indicated on the far left in kilodaltons (kDa)
(ctrl = sham; PD = pre-motor PD models).
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Figure 5. Venn diagram showing deiminated protein hits identified in plasma and plasma-EVs of
pre-motor PD model and of sham rats. (A) A considerable higher number of deiminated protein hits
was identified in plasma of the pre-motor PD model rats, compared with that in shams, with some
overlapping protein hits. (B) A higher number of protein hits was identified to be deiminated in
circulating plasma-EVs of the pre-motor PD rat models, compared with that in shams, with some
hits overlapping.
STRING analysis of the KEGG pathways identified for deiminated protein hits in total plasma of
the pre-motor PD model and sham-treated rat plasma respectively, is shown in Figure 6 (Figure 6A,B;
see also Tables 1 and 2 as well as Supplementary Tables S1 and S2 for full LC-MS/MS data analysis
of all protein hits). In whole plasma, KEGG pathways enriched in deimination and found to be
common between shams and pre-motor PD models whole plasma were “complement and coagulation
cascades” and “oestrogen signalling pathway” (Figure 6A,B). KEGG pathways identified to be enriched
in deiminated proteins in the pre-motor PD models compared to plasma from sham-treated rats
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were KEGG pathways for “Parkinson’s disease”, “Alzheimer’s disease”, “Huntington’s disease” and
“prion disease”, “retrograde endocannabinoid signalling”, “systemic lupus erythematosus (SLE)”,
and “non-alcoholic fatty liver disease (NAFLD)” (Figure 6B). Pathways identified as enriched in
deiminated proteins in sham plasma only belonged to “cholesterol metabolism”, “fat digestion and
absorption”, “vitamin digestion and absorption”, “platelet activation”, “PPAR signalling pathway”,
“African trypanosomiasis”, “S. aureus infection”, and “malaria” (Figure 6A).
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Table 1. Deiminated proteins in sham-treated rat plasma (Rattus norvegicus), as identified
by F95-enrichment and liquid chromatography mass spectrometry (LC-MS/MS) analysis.
Deiminated proteins were isolated from sham-treated rat plasma by immunoprecipitation using
the pan-deimination F95 antibody. The resulting F95-enriched eluate was then analysed by LC-MS/MS
and peak list files submitted to mascot. Rattus norvegicus species-specific peptide sequence hits are
listed, showing number of sequences for protein hits and total score. Blue highlighted rows indicate
protein hits identified in whole plasma of sham-treated rats, but not identified as deiminated in plasma
of the pre-motor PD model.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Serum albumin A0A0G2JSH5_RAT 38 2280
Serum albumin ALBU_RAT 37 2215
Alpha-1-macroglobulin A1M_RAT 34 1890
Alpha-1-inhibitor 3 A1I3_RAT 25 1615
Complement C3 M0RBF1_RAT 30 1611
Similar to histidine-rich glycoprotein A0A0G2K9Y5_RAT 28 1561
Murinoglobulin-1 D4A6E3_RAT 22 1330
Kininogen-1 KNG1_RAT 20 1112
Ac1873 Q7TQ70_RAT 21 1008
Serotransferrin TRFE_RAT 18 936
Isoform LMW of Kininogen-1 KNG1_RAT 15 860
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Table 1. Cont.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Ig gamma-2C chain C region IGG2C_RAT 13 739
Isoform 2 of Fibrinogen beta chain FIBB_RAT 14 545
Ig gamma-2A chain C region IGG2A_RAT 8 520
Isoform Gamma-A of Fibrinogen gamma chain FIBG_RAT 10 516
Carboxypeptidase N catalytic chain CBPN_RAT 8 460
Uncharacterized protein A0A0G2JZW1_RAT 8 446
C-reactive protein CRP_RAT 6 432
Fibronectin A0A096P6L8_RAT 9 404
Ig kappa chain C region, A allele KACA_RAT 6 383
Uncharacterized protein A0A0G2JVP4_RAT 7 341
Uncharacterized protein A0A0G2K477_RAT 6 333
Hemoglobin subunit beta-1 HBB1_RAT 6 319
Apolipoprotein E A0A0G2K151_RAT 7 316
Uncharacterized protein D4ACR1_RAT 4 300
Hemoglobin subunit alpha-1/2 HBB1_RAT 6 295
Uncharacterized protein D4ACR1_RAT 4 274
Kininogen-1 A0A0G2JVQ5_RAT 6 251
Carboxypeptidase N subunit 2 F1LQT4_RAT 6 250
Ig gamma-2B chain C region IGG2B_RAT 5 237
Hemopexin HEMO_RAT 6 231
Ceruloplasmin A0A0G2K9I6_RAT 6 220
Hemoglobin subunit beta-2 HBB2_RAT 4 216
Uncharacterized protein M0RA79_RAT 3 213
Keratin, type II cytoskeletal 5 A0A0G2K509_RAT 3 210
Alpha-1-antiproteinase A0A0G2JY31_RAT 3 209
Uncharacterized protein A0A0G2K290_RAT 3 203
Keratin, type II cytoskeletal 6A K2C6A_RAT 3 198
Ab1-233 A0A0G2JXK5_RAT 4 197
Uncharacterized protein F1LVL4_RAT 3 186
Keratin, type I cytoskeletal 14 K1C14_RAT 3 181
Uncharacterized protein F1M3 × 3_RAT 4 177
Kallikrein B, plasma 1 Q5FVS2_RAT 3 175
Complement C2 Q6MG73_RAT 4 175
Uncharacterized protein A0A0G2JY98_RAT 3 172
Haptoglobin A0A0H2UHM3_RAT 3 151
Selenoprotein P SEPP1_RAT 4 151
Apolipoprotein A-I APOA1_RAT 2 134
Serine protease inhibitor A3K SPA3K_RAT 4 130
Uncharacterized protein F1LXY6_RAT 2 123
Uncharacterized protein A0A0G2JW41_RAT 1 115
Keratin 16 Q6IFU9_RAT 3 115
Ig lambda-2 chain C region LAC2_RAT 2 112
Uncharacterized protein A0A0G2K4K2_RAT 3 111
Coagulation factor XII A0A0H2UI19_RAT 3 110
Inter-alpha-trypsin inhibitor heavy chain family, member 4 D3ZFC6_RAT 2 105
Uncharacterized protein F1LZH0_RAT 2 93
Uncharacterized protein F1M0U4_RAT 2 93
RCG21066 D3ZJW6_RAT 2 86
Uncharacterized protein M0RAB8_RAT 1 85
Uncharacterized protein M0R816_RAT 1 83
C-type lectin domain family 11 member A CLC11_RAT 2 80
Complement factor H F1M983_RAT 2 79
Beta-globin Q62669_RAT 2 71
Uncharacterized protein A0A0G2JV42_RAT 2 62
Uncharacterized protein F1LM19_RAT 1 53
Inter-alpha-trypsin inhibitor heavy chain 2 D3ZFH5_RAT 2 53
Uncharacterized protein F1M5L5_RAT 2 52
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Fetub protein Q6IRS6_RAT 1 45
Uncharacterized protein A0A0G2JWX0_RAT 1 45
Uncharacterized protein A0A0G2JTG4_RAT 1 42
Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1_RAT 1 41
Uncharacterized protein A0A0G2JUY3_RAT 1 41
Apolipoprotein A-IV A0A0G2JVX7_RAT 1 39
Extracellular calcium-sensing receptor CASR_RAT 1 37
Uncharacterized protein F1LZ11_RAT 1 36
Uncharacterized protein M0R9U2_RAT 1 34
Golgi apparatus protein 1 G3V8G5_RAT 1 33
Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions
scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a
non-probabilistic basis for ranking protein hits.
Table 2. Deiminated proteins in pre-motor PD rat plasma (Rattus norvegicus), as identified by
F95-enrichment and LC-MS/MS analysis. Deiminated proteins from pre-motor PD rat plasma were
isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched
eluate was then analysed by LC-MS/MS and peak list files submitted to mascot. Rattus norvegicus
species-specific peptide sequence hits are listed, showing number of sequences for protein hits and
total score. Pink highlighted rows indicate protein hits identified in pre-motor PD plasma but not
sham-treated rat plasma.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Complement C3 M0RBF1_RAT 89 5530
Alpha-1-macroglobulin A1M_RAT 74 4911
Alpha-1-inhibitor 3 A1I3_RAT 59 3845
Fibronectin A0A096P6L8_RAT 64 3722
Murinoglobulin-1 MUG1_RAT 57 3618
Serum albumin ALBU_RAT 56 3564
Serum albumin A0A0G2JSH5_RAT 56 3550
Fibrinogen beta chain FIBB_RAT 53 3399
Serotransferrin TRFE_RAT 53 3384
Ac1873 Q7TQ70_RAT 56 3317
Isoform Gamma-A of Fibrinogen gamma chain FIBG_RAT 31 2185
Similar to histidine-rich glycoprotein A0A0G2K9Y5_RAT 38 2137
Kininogen-1 KNG1_RAT 33 1981
Complement C2 Q6MG73_RAT 30 1875
Ceruloplasmin A0A0G2K9I6_RAT 32 1816
Complement factor H G3V9R2_RAT 28 1570
Kallikrein B, plasma 1 Q5FVS2_RAT 27 1552
Ig gamma-2C chain C region IGG2C_RAT 21 1447
Complement factor B A0A0U1RRP9_RAT 24 1405
Hemopexin HEMO_RAT 25 1388
Keratin, type II cytoskeletal 5 K2C5_RAT 24 1284
Uncharacterized protein G3V9J1_RAT 22 1197
Inter alpha-trypsin inhibitor, heavy chain 4 Q5EBC0_RAT 22 1192
Carboxypeptidase N catalytic chain CBPN_RAT 18 1172
Uncharacterized protein A0A0G2JVP4_RAT 18 1133
Ig gamma-2A chain C region IGG2A_RAT 16 1108
Complement C4 CO4_RAT 20 1070
Carboxypeptidase N subunit 2 F1LQT4_RAT 19 1042
Plasminogen PLMN_RAT 20 1001
Apolipoprotein A-IV APOA4_RAT 17 989
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Uncharacterized protein A0A0G2JZW1_RAT 13 980
Inter-alpha trypsin inhibitor, heavy chain 1 B2RYM3_RAT 18 960
Complement C5 A0A096P6L9_RAT 21 959
Apolipoprotein E A0A0G2K151_RAT 13 813
Keratin, type I cytoskeletal 14 K1C14_RAT 14 779
Complement C4B (Chido blood group) Q6MG90_RAT 13 769
Ab1-233 A0A0G2JYK0_RAT 14 760
Inter-alpha-trypsin inhibitor heavy chain 2 D3ZFH5_RAT 15 755
Uncharacterized protein F1LTJ5_RAT 14 735
Serine protease inhibitor A3L SPA3L_RAT 14 734
Serine protease inhibitor A3K SPA3K_RAT 12 685
Keratin, type I cytoskeletal 42 K1C42_RAT 12 660
Uncharacterized protein A0A0G2K477_RAT 11 656
Haptoglobin A0A0H2UHM3_RAT 14 650
Keratin, type I cytoskeletal 17 A0A0G2K9Q9_RAT 14 634
Alpha-1-antiproteinase A0A0G2JY31_RAT 11 613
Inter-alpha-trypsin inhibitor heavy chain H3 D3ZBS2_RAT 13 610
Selenoprotein P SEPP1_RAT 9 590
C-type lectin domain family 11 member CLC11_RAT 12 587
Uncharacterized protein M0RA79_RAT 10 571
Apolipoprotein A-I APOA1_RAT 10 558
C-reactive protein CRP_RAT 7 554
Coagulation factor XII A0A0H2UI19_RAT 11 550
Ig kappa chain C region, A allele KACA_RAT 7 536
Uncharacterized protein F1M3X3_RAT 9 536
Insulin-like growth factor binding protein, acid
labile subunit, isoform CRA_b F1LRE2_RAT 9 529
Kininogen-1 A0A0G2JVQ5_RAT 9 524
Uncharacterized protein F1LXY6_RAT 7 507
Keratin 16 Q6IFU9_RAT 9 504
Uncharacterized protein A0A0G2K828_RAT 7 500
Keratin, type II cytoskeletal 75 A0A0H2UHH5_RAT 9 496
Uncharacterized protein D4ACR1_RAT 8 471
Apolipoprotein B-100 F1M6Z1_RAT 12 457
Keratin, type II cytoskeletal 6A K2C6A_RAT 9 446
Keratin, type II cytoskeletal 8 K2C8_RAT 8 435
Apolipoprotein H Q5I0M1_RAT 9 435
Uncharacterized protein D3ZZ08_RAT 7 433
Ig gamma-2B chain C region IGG2B_RAT 8 433
Carboxylesterase 1C EST1C_RAT 8 431
Hemoglobin subunit alpha-1/2 HBA_RAT 8 411
Angiopoietin-like 6 B2RYM1_RAT 8 407
Alpha-2-HS-glycoprotein FETUA_RAT 8 403
Uncharacterized protein M0R9U2_RAT 6 403
Hemoglobin subunit beta-1 HBB1_RAT 6 380
Uncharacterized protein A0A0G2K290_RAT 6 378
Uncharacterized protein F1LZ11_RAT 7 373
Ig lambda-2 chain C region LAC2_RAT 6 340
Uncharacterized protein M0RAB8_RAT 5 330
Fetub protein Q6IRS6_RAT 7 314
Int. J. Mol. Sci. 2020, 21, 2743 10 of 37
Table 2. Cont.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Uncharacterized protein D4A3D1_RAT 5 312
Afamin G3V9R9_RAT 7 312
Keratin, type I cytoskeletal 19 K1C19_RAT 7 308
Uncharacterized protein A0A0G2JUY4_RAT 5 307
Uncharacterized protein M0RDF2_RAT 5 281
Uncharacterized protein M0RBK4_RAT 3 272
Uncharacterized protein A0A0G2JY98_RAT 4 268
Uncharacterized protein A0A0G2JXP0_RAT 4 257
Extracellular matrix protein 1 ECM1_RAT 5 255
Group specific component Q68FY4_RAT 6 247
Desmoplakin F1LMV6_RAT 6 244
Vitronectin Q3KR94_RAT 6 233
Uncharacterized protein M0RAV0_RAT 3 225
Peptidoglycan recognition protein 2 M0R485_RAT 5 220
Uncharacterized protein A0A0G2K7I1_RAT 2 211
Uncharacterized protein A0A0G2JW41_RAT 2 210
Uncharacterized protein A0A0G2K7P6_RAT 3 204
Glutathione peroxidase A0A0G2K531_RAT 4 201
Uncharacterized protein A0A0G2JTG4_RAT 3 200
Uncharacterized protein F1LVL4_RAT 3 199
C4b-binding protein alpha chain C4BPA_RAT 6 196
RCG21066 D3ZJW6_RAT 4 194
Alpha-2-macroglobulin A2MG_RAT 4 194
Uncharacterized protein A0A0G2K304_RAT 4 193
Uncharacterized protein A0A0G2K4I8_RAT 4 188
Uncharacterized protein M0R693_RAT 4 187
Complement C1q subcomponent subunit B G3V7N9_RAT 3 186
T-kininogen 1 KNT1_RAT 4 174
Uncharacterized protein A0A0G2K332_RAT 3 169
Protein AMBP AMBP_RAT 2 169
Uncharacterized protein A0A0G2JZV7_RAT 3 164
Uncharacterized protein A0A0G2JXB7_RAT 4 161
Uncharacterized protein M0RD98_RAT 2 161
Junction plakoglobin PLAK_RAT 2 154
Actin, cytoplasmic 1 A0A0G2K3K2_RAT 3 153
Uncharacterized protein A0A0G2JV42_RAT 2 153
Uncharacterized protein F1M7B3_RAT 2 151
Uncharacterized protein A0A0G2K245_RAT 2 150
Uncharacterized protein M0R4Z4_RAT 3 142
Uncharacterized protein F1M1R0_RAT 2 138
Uncharacterized protein F1LYF1_RAT 2 134
Complement C8 gamma chain D3ZPI8_RAT 2 134
Uncharacterized protein D3ZC54_RAT 2 133
Uncharacterized protein F1M3E9_RAT 3 132
CD5 antigen-like Q4KM75_RAT 2 129
Collagen type XVIII alpha 1 chain F1LR02_RAT 2 128
Serpin family F member 2 F7FHF3_RAT 2 126
Uncharacterized protein M0R628_RAT 2 124
Uncharacterized protein G3V8Z5_RAT 3 118
Uncharacterized protein F1LZH0_RAT 2 117
Ab1-233 A0A0H2UHI5_RAT 2 105
Papilin, proteoglycan-like sulfated glycoprotein D3ZD40_RAT 3 104
Uncharacterized protein A0A0G2K3K8_RAT 2 104
Uncharacterized protein F1LWS4_RAT 3 103
Uncharacterized protein D3ZPL2_RAT 1 101
Uncharacterized protein D4A4L6_RAT 2 101
Uncharacterized protein M0R816_RAT 1 99
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Glutamine synthetase GLNA_RAT 3 99
Uncharacterized protein A0A0G2K5D2_RAT 2 98
Uncharacterized protein F1M663_RAT 1 96
Uncharacterized protein M0R8G6_RAT 1 93
Uncharacterized protein M0R8Q4_RAT 1 91
Uncharacterized protein F1LWD0_RAT 2 91
Similar to RIKEN cDNA A0A0G2K896_RAT 2 86
Uncharacterized protein M0R5A0_RAT 2 83
Uncharacterized protein F1M5L5_RAT 2 77
Uncharacterized protein D3ZFF8_RAT 2 75
Uncharacterized protein A0A0G2K4K2_RAT 2 73
Prothrombin G3V843_RAT 2 73
Uncharacterized protein M0R7Q2_RAT 2 69
Uncharacterized protein A0A096P6M7_RAT 1 65
Tripartite motif-containing 33 D3ZUK4_RAT 2 65
Uncharacterized protein M0R8B5_RAT 1 61
Uncharacterized protein M0R4C5_RAT 1 60
Ig kappa chain V region S211 KVX01_RAT 1 59
Uncharacterized protein F1LTY5_RAT 1 57
Uncharacterized protein M0R4G1_RAT 1 55
Suprabasin F7FEM5_RAT 1 53
NADH:ubiquinone oxidoreductase subunit B10 D4A0T0_RAT 2 52
Complement C1q subcomponent subunit A C1QA_RAT 1 52
Ciliary rootlet coiled-coil, rootletin F1M6Q2_RAT 2 52
E3 ubiquitin-protein ligase HUWE1 A0A0G2JVW5_RAT 2 52
Complement factor properdin B0BNN4_RAT 1 52
Uncharacterized protein A0A0G2JX36_RAT 1 51
Tubulin beta-2B chain TBB2B_RAT 1 51
Uncharacterized protein A0A0G2K0N6_RAT 1 50
Cadherin-1 CADH1_RAT 1 46
Caspase 8-associated protein 2 D4A7V6_RAT 2 46
Phospholipase A2 A0A0G2JZ44_RAT 1 46
PEX5-related protein F1LMT5_RAT 2 44
Collectin sub-family member 11 F1LSS7_RAT 1 44
Oxysterol-binding protein A0A0G2K0D5_RAT 2 43
Uncharacterized protein F1M6N0_RAT 1 42
Obscurin-like protein 1 OBSL1_RAT 2 42
Serum amyloid A protein Q5M878_RAT 1 41
Proline-rich protein 5 A0A0H2UHJ6_RAT 1 41
Complement component C9 F7F389_RAT 1 39
Methyltransferase-like 3 Q4V8G6_RAT 1 36
Complement C8 alpha chain D3ZWD6_RAT 1 35
Serine (Or cysteine) peptidase inhibitor, clade C
(Antithrombin), member 1 Q5M7T5_RAT 1 33
Cell cycle checkpoint control protein RAD9B RAD9B_RAT 1 33
Heparin cofactor 2 A0A0G2K8K3_RAT 1 33
Histone H4 H4_RAT 1 33
Uncharacterized protein (Fragment) A0A096MK45_RAT 1 32
Phosphatidylinositol glycan anchor biosynthesis, class Q Q642B8_RAT 1 32
Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions
scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a
non-probabilistic basis for ranking protein hits.
The KEGG pathways identified for deiminated protein hits in plasma-EVs of the pre-motor PD
models and sham-treated rats are shown in Figure 7 (Figure 7A,B; see also Tables 3 and 4 as well as
Supplementary Tables S3 and S4 for full LC-MS/MS data analysis of all protein hits). Deiminated proteins
in plasma-EVs of the pre-motor PD models were enriched in KEGG pathways for “Parkinson’s disease”,
“Alzheimer’s disease”, and “Huntington’s disease”, while none of these KEGG pathways were identified
for deiminated protein hits in sham-treated rat plasma-EVs (Figure 7A,B). Furthermore, pathways
for “oxidative phosphorylation”, “complement coagulation cascades”, “thermogenesis”, “metabolic
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pathways”, “S. aureus infection”, “gap junction”, “platelet activation”, and “apelin signalling” were
only identified in plasma-EVs from the pre-motor PD models (Figure 7B). “Oestrogen signalling
pathway” was common to EVs of both PD and sham-treated rat plasma. In addition, pathways
enriched in deiminated proteins in sham-treated plasma-EVs and not identified in the PD models
belonged to “cell cycle”, “progesterone mediated oocyte maturation”, “Epstein Barr virus infection”,
“antigen processing and presentation”, “viral carcinogenesis”, “HTLV-1 infection”, “ubiquitin mediated
proteolysis”, “protein processing in ER”, “cellular senescence”, “longevity regulating pathway”,
“glycolysis”, and “p53 signalling pathway” (Figure 7A).
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Table 3. Deiminated proteins in plasma-EVs of sham-treated rats (Rattus norvegucus), as identified by
Figure 95. and LC-MS/MS analysis. Deiminated proteins in sham-treated rat plasma were isolated by
immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched eluate was
then analysed by LC-MS/MS and peak list files submitted to mascot. Rattus norvegicus species-specific
peptide sequence hits are listed, showing number of sequences for protein hits and total score.
Green highlighted rows indicate protein hits identified in sham-treated (control) rat plasma only.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Serum albumin A0A0G2JSH5_RAT 13 829
RCG36700 A0A0G2K3G0_RAT 13 654
Keratin, type II cytoskeletal 5 K2C5_RAT 14 624
Keratin, type I cytoskeletal 17 A0A0G2K9Q9_RAT 12 571
Keratin, type I cytoskeletal 14 K1C14_RAT 8 500
Actin, cytoplasmic 1 A0A0G2K3K2_RAT 8 461
Keratin, type II cytoskeletal 6A K2C6A_RAT 8 401
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Keratin, type I cytoskeletal 19 K1C19_RAT 9 391
Keratin 16 Q6IFU9_RAT 6 368
Heat shock protein HSP 90-beta A0A0G2K793_RAT 9 337
Keratin, type II cytoskeletal 8 K2C8_RAT 6 330
Keratin, type II cytoskeletal 75 A0A0H2UHH5_RAT 7 320
Heat shock 70 kDa protein 1A HS71A_RAT 5 312
Heat shock protein HSP 90-alpha HS90A_RAT 7 298
Uncharacterized protein A0A0G2K828_RAT 4 284
Ig gamma-2A chain C region IGG2A_RAT 5 281
Isoform LMW of Kininogen-1 KNG1_RAT 6 272
Alpha-1-macroglobulin A1M_RAT 8 267
Keratin, type I cytoskeletal 42 K1C42_RAT 5 265
Heat shock 70 kDa protein 1-like HS71L_RAT 4 257
Complement C3 M0RBF1_RAT 6 238
Ig gamma-2C chain C region IGG2C_RAT 5 224
Serotransferrin A0A0G2QC06_RAT 5 222
Uncharacterized protein D4ACR1_RAT 3 179
Murinoglobulin-1 A0A0G2JUP5_RAT 3 148
Ig kappa chain C region, A allele KACA_RAT 2 142
Desmoplakin F1LMV6_RAT 3 131
C-reactive protein A0A0G2K8V5_RAT 2 119
Histone H4 H4_RAT 2 109
14-3-3 protein theta 1433T_RAT 2 103
40S ribosomal protein RSSA_RAT 1 93
Elongation factor 1-alpha M0R757_RAT 2 87
Ubiquitin-like modifier-activating enzyme 1 UBA1_RAT 2 87
Ig gamma-2B chain C region IGG2B_RAT 2 82
Uncharacterized protein A0A0G2JUY4_RAT 1 82
L-lactate dehydrogenase A chain LDHA_RAT 2 69
Uncharacterized protein M0RA79_RAT 1 66
Apolipoprotein E A0A0G2K151_RAT 1 64
Globin a4 A0A0G2JSW3_RAT 1 63
Uncharacterized protein A0A0G2K980_RAT 1 60
Uncharacterized protein D3ZE63_RAT 1 57
Histone H2A.Z H2AZ_RAT 2 55
Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4_RAT 1 55
Peroxiredoxin-2 A0A0G2JSH9_RAT 1 55
L-lactate dehydrogenase B chain LDHB_RAT 2 54
Eukaryotic initiation factor 4A-II A0A0G2K8B7_RAT 2 52
Clathrin heavy chain F1M779_RAT 1 49
Tubulin alpha chain A0A0H2UHM7_RAT 1 49
Uncharacterized protein A0A096P6M7_RAT 1 46
cAMP responsive element binding protein
3, isoform CRA A0A0G2K331_RAT 2 45
Transportin 1 F1LQP9_RAT 1 44
Unconventional myosin-Va A0A0G2K4Y7_RAT 2 44
6-phosphogluconate dehydrogenase,
decarboxylating A0A0G2K7Q8_RAT 1 43
Uncharacterized protein A0A0G2K8S2_RAT 1 41
Phospholipase A2 A0A0G2JZ44_RAT 1 41
Histone H2B A0A0G2JXE0_RAT 1 40
Ventricular zone-expressed PH
domain-containing protein homolog 1 A0A0G2K6S2_RAT 1 40
Uncharacterized protein A0A0G2JVP4_RAT 1 37
Pyruvate kinase A0A0G2JVG3_RAT 1 37
Centromere protein E D3ZV60_RAT 1 36
Methyltransferase-like 3 Q4V8G6_RAT 1 35
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Transketolase G3V826_RAT 1 35
Uncharacterized protein A0A0G2KB28_RAT 1 35
Enhancer of mRNA-decapping protein 4 EDC4_RAT 1 35
T-complex protein 1 subunit eta D4AC23_RAT 1 34
Signal-induced proliferation-associated 1 E9PSX8_RAT 1 34
Stress-70 protein, mitochondrial F1M953_RAT 1 32
Filamin-C A0A0H2UHR7_RAT 1 32
Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions
scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a
non-probabilistic basis for ranking protein hits.
Table 4. Deiminated proteins in plasma-EVs of pre-motor PD rats (Rattus norvegicus), as identified
by F95-enrichment and LC-MS/MS analysis. Deiminated proteins in pre-motor PD rat plasma were
isolated by immunoprecipitation using the pan-deimination F95 antibody. The resulting F95-enriched
eluate was then analysed by LC-MS/MS and peak list files submitted to mascot. Rattus norvegicus
species-specific peptide sequence hits are listed, showing number of sequences for protein hits and
total score. Orange highlighted rows indicate protein hits identified in plasma-EVs of pre-motor PD
rats, but not in plasma-EVs of sham-treated rats.
Protein Name Symbol Sequences
Total Score
(p < 0.05)
Serum albumin ALBU_RAT 41 2238
Alpha-1-macroglobulin A1M_RAT 33 1650
Keratin, type II cytoskeletal 5 K2C5_RAT 29 1395
Similar to histidine-rich glycoprotein A0A0G2K9Y5_RAT 28 1305
Serotransferrin TRFE_RAT 28 1238
Alpha-1-inhibitor A1I3_RAT 21 976
Kininogen-1 KNG1_RAT 17 898
Complement C3 M0RBF1_RAT 16 815
Keratin, type II cytoskeletal 75 A0A0H2UHH5_RAT 13 714
Ig gamma-2C chain C region IGG2C_RAT 14 699
Murinoglobulin-1 A0A0G2JUW7_RAT 15 683
Ig gamma-2A chain C region IGG2A_RAT 12 670
Keratin, type I cytoskeletal 17 A0A0G2K9Q9_RAT 14 663
Keratin, type II cytoskeletal 6A K2C6A_RAT 12 649
Keratin, type II cytoskeletal 1b A0A0G2JZQ9_RAT 12 595
Keratin, type I cytoskeletal 14 K1C14_RAT 12 592
Actin, cytoplasmic 1 A0A0G2K3K2_RAT 11 539
Desmoplakin F1LMV6_RAT 14 523
Keratin, type II cytoskeletal 8 K2C8_RAT 10 503
Junction plakoglobin PLAK_RAT 10 481
Keratin, type I cytoskeletal 42 K1C42_RAT 11 472
Uncharacterized protein A0A0G2JVP4_RAT 9 447
Uncharacterized protein A0A0G2JVP4_RAT 7 417
Keratin 16 Q6IFU9_RAT 9 413
C-reactive protein CRP_RAT 6 325
Uncharacterized protein M0RA79_RAT 5 303
Tubulin alpha-1B chain TBA1B_RAT 7 296
Uncharacterized protein A0A0G2K9Y0_RAT 6 293
Ig kappa chain C region, A allele KACA_RAT 6 280
Ac1873 Q7TQ70_RAT 7 256
Tubulin beta-5 chain TBB5_RAT 5 246
Tubulin beta-2B chain TBB2B_RAT 5 244
Tubulin beta-4B chain TBB4B_RAT 5 229
Isoform Long of Annexin A2 ANXA2_RAT 3 228
Histone H4 H4_RAT 4 221
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Uncharacterized protein A0A0G2K290_RAT 4 218
Isoform Gamma-A of Fibrinogen gamma chain FIBG_RAT 4 215
Carboxypeptidase N catalytic chain CBPN_RAT 6 202
Uncharacterized protein A0A0G2K828_RAT 3 176
Histone H2B A0A0G2JXE0_RAT 3 172
Neurofilament heavy polypeptide F1LRZ7_RAT 3 164
Keratin 83 A0A0G2JUU5_RAT 4 150
Uncharacterized protein A0A0G2K3S3_RAT 2 137
Uncharacterized protein M0RD98_RAT 2 132
Hemopexin HEMO_RAT 4 130
Ig gamma-2B chain C region IGG2B_RAT 3 129
Uncharacterized protein D4ACR1_RAT 2 126
Carboxypeptidase N subunit 2 F1LQT4_RAT 3 123
Keratinocyte proline-rich protein G3V9A5_RAT 3 122
Uncharacterized protein F1LXY6_RAT 2 116
Plakophilin 1 D3ZY51_RAT 2 115
Selenoprotein P SEPP1_RAT 3 106
Uncharacterized protein F1M3X3_RAT 2 102
Apolipoprotein E A0A0G2K151_RAT 3 97
Epsilon 1 globin O88752_RAT 1 91
Globin c2 A0A0G2JSV6_RAT 2 82
Keratin 78 (Fragment) A0A0G2JUR6_RAT 2 81
Isoform 2 of Fibrinogen beta chain FIBB_RAT 2 81
Keratin, type I cytoskeletal 40 K1C40_RAT 2 80
Uncharacterized protein A0A096P6M7_RAT 1 80
Neurofilament medium polypeptide G3V7S2_RAT 2 73
Vitronectin Q3KR94_RAT 2 72
Heat shock 70 kDa protein 1A HS71A_RAT 2 72
Uncharacterized protein A0A0G2K6T8_RAT 2 69
Uncharacterized protein F1M6N0_RAT 2 66
Ras homolog family member C A0A0G2K6E0_RAT 1 64
Chymotrypsinogen B F1MA56_RAT 2 61
Uncharacterized protein A0A0G2JZV7_RAT 1 59
Lactadherin A0A0G2K506_RAT 1 57
Uncharacterized protein A0A0G2JTG4_RAT 1 56
Uncharacterized protein A0A0G2K099_RAT 1 51
Uncharacterized protein A0A0G2JV42_RAT 1 51
Dystrophin DMD_RAT 2 50
Cell division control protein 42 homolog A0A0G2JSM8_RAT 1 50
Ig lambda-2 chain C region LAC2_RAT 2 49
Uncharacterized protein M0RBK4_RAT 1 43
Desmoglein 1 D3ZM39_RAT 1 42
Elongation factor 1-alpha M0R757_RAT 1 42
Uncharacterized protein A0A0G2K4K2_RAT 2 41
Cationic trypsinogen G3V7Q8_RAT 1 41
Histidine ammonia-lyase HUTH_RAT 1 40
Trypsin V-A TRYA_RAT 1 39
Cingulin D4A4X4_RAT 1 39
Uncharacterized protein A0A0G2K8S2_RAT 1 39
Centrosomal protein 290 A0A0G2K715_RAT 1 39
Proline-rich protein 5 A0A0H2UHJ6_RAT 1 38
Uncharacterized protein A0A0G2JUY3_RAT 1 38
Uncharacterized protein M0RAB8_RAT 1 37
Spliceosome RNA helicase Ddx39b A0A0G2KAT4_RAT 1 37
Uncharacterized protein A0A0G2K0N8_RAT 1 37
Complement factor B (Fragment) A0A096MKF9_RAT 1 36
Methyltransferase-like 3 Q4V8G6_RAT 1 35
Golgi apparatus protein 1 G3V8G5_RAT 1 35
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Protein Name Symbol Sequences
Total Score
(p < 0.05)
Ceruloplasmin A0A0G2K9I6_RAT 1 35
Histone H2A.Z H2AZ_RAT 1 35
DNA-(apurinic or apyrimidinic site) lyase D3ZPZ3_RAT 1 34
Keratin, type II cytoskeletal 80 K2C80_RAT 1 33
Uncharacterized protein (Fragment) A0A096MK45_RAT 1 32
Ions score is −10*Log(P), where P is the probability that the observed match is a random event. Individual ions
scores > 31 indicated identity or extensive homology (p < 0.05). Protein scores were derived from ions scores as a
non-probabilistic basis for ranking protein hits.
2.4. Deiminated Proteins are Increased in Brain Tissue of Pre-Motor PD Rats
The pre-motor PD model brains presented an increased level of F95 immuno-positive staining
compared with that of sham-treated brains. A strong positive staining for pan-deiminated proteins,
by F95 detection, was observed in the cortex and hippocampus, as well as in white matter, with a
highly notable positive staining in the brain vasculature (Figure 8A–C). F95 immuno-positive protein
detection, assessed by thresholding intensity, showed an increase by 1.7-fold (p ***; p < 0.001) in the
cortex and by 1.4-fold (p ***; p < 0.001) in the hippocampal CA1 region (Figure 8D,E), compared
with shams.
Immunohistochemical staining for deiminated histone H3 (citH3) also revealed increased detection
in brains of pre-motor PD models, compared with shams. CitH3 positive staining was increased in the
dentate gyrus (Figure 9A), and cortex (Figure 9B) of the pre-motor PD brains, compared with shams.
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(ctx) of the pre-motor PD rat brains compared with that in the sham control brains. (B) Increased 
protein deimination is observed in white matter (wm) of the pre-motor PD rat brains compared with 
sham brains. (C) Increased protein deimination (F95 positive) is observed in the hippocampus (hip) 
of the pre-motor PD rat brains, compared with sham brains; the scale bars indicate 100 µm in all 
figures (ctx=cortex, hip=hippocampus, wm=white matter). (D,E) Thresholding intensity analysis of 
F95 positive staining showed a significant increase in the cortex (D), and the CA1 region of the 
hippocampus (E) of pre-motor PD models, compared with that in control sham brains (unpaired t-
test, ***p < 0.001). 
Immunohistochemical staining for deiminated histone H3 (citH3) also revealed increased 
detection in brains of pre-motor PD models, compared with shams. CitH3 positive staining was 
increased in the dentate gyrus (Figure 9A), and cortex (Figure 9B) of the pre-motor PD brains, 
compared with shams. 
 
Figure 8. Total deiminated proteins are increased in brain tissue of pre-motor PD rats. Total deiminated
protein expression was assessed by immunohistoch mistry usi g the pan-deimination F95 antibody.
(A) Incre s r tei deiminatio is observed in the brain vasculatur in the cortex (ctx) of the pre-motor
PD rat brains compared with that in the sham control brains. (B) Increased protein deimination is
observed in white atter (wm) of the pre-motor PD rat brains compared with sham brains. (C) Increased
protein deimination (F95 positive) is observed in the hippocampus (hip) of the pre-motor PD rat brains,
compared with sham brains; the scale bars indicate 100µm in all figures (ctx = cortex, hip = hippocampus,
wm = white atter). (D,E) Thresholding intensity analysis of F95 positive staining showed a significant
increase in the cortex (D), and the CA1 region of the hippocampus (E) of pre-motor PD models,
compared with that in control sham brains (unpaired t-test, *** p < 0.001).
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Figure 9. Deiminated histone H3 staining is increased in the cortex and dentate gyrus of pre-motor PD
models. Immunohistochemical staining showed increased protein detection of deiminated histone H3
(citH3) in: (A)) the dentate gyrus; (B) the cortex of the pre-motor PD models, compared with those in
the control sham animals. The scale bars indicate 100 µm in all figures.
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Immunoreactivity for PAD2, PAD3, and PAD4 was also confirmed in both sham-treated and
pre-motor PD model brains, with some elevated protein levels for PAD4 observed in the pre-motor
PD model, while PAD3 showed a slight elevation and PAD2 levels were not markedly changed in the
pre-motor PD models (Figure 10A–C).
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(A) PAD2 protein detection in cortex (ctx), white matter (wm) and hippocampus (hip) of sham and
pre-motor PD models. (B) PAD3 protein detection in cortex, white matter, and hippocampus of shams
and pre-motor PD rats. (C) PAD4 protein detection in cortex, white matter and hippocampus of shams
and pre-motor PD rats. The scale bars indicate 100 µm in all figures (ctx = cortex, hip = hippocampus,
wm = white matter).
3. Discussion
The regulation of EV release is critical for cellular communication, and particularly for the
modulation of he cellular microenvironment in a range f pathologies. Mounting evidence has
linked EVs to neurodegenerativ diseases, indic ting critical roles for EV-med ated transport of
pathogenic prot in and genetic cargo, includ g in PD [21,22]. H weve , roles for such EV-mediated
commu ati n i early stages of PD have received limited attention. To this end, a rat pre- otor PD
model was used in this study. While this mod l may no display all the signs observed in PD patients,
it has been show o di pla some non-motor symptoms (hyposmia and cognitive impairment) in the
absenc of motor dysfunction. This model allows therefore a valuable insight into the time wi dow
prior to the appearance of typical PD motor symptoms and highlight potential markers of early s ages
of the disease. The small sampl sizes in each experimental group are justified by he clear statistical
differences observe b tween the sham nimal and pr -motor models indicating good compliance of
this study o the 3Rs principle .
R les for peptidylarginine deiminases (PADs) and post-translational deimination in various
neurod generative diseases are an area of increasing interest. Data from a human RNA-Seq
transcriptome and splicing database of glia, eurones, and vascular cells of t e cerebral cortex
h ve shown th t leve s of PAD2 are highest i matur astrocytes, oligodendrocytes, and mic oglia [28].
In the majority of studies of protein deimination in neurodegenerative diseas focus has so far been
on hist logical analysis of p stmorte human brain sampl s wi h increased p n-protein deimination
detec ed in both PD and Alzheimer’s disease (AD) [10,11,29–31]. Deimination has hitherto not been
assessed in pre-motor PD and was therefore the subject of our current study as such post-translationally
mediated changes may result in early onset pro-inflammatory and neurodegenerative processes and
therefore offer an opportunity for early intervention. Interestingly, in the current study using a rat
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model of pre-motor PD, that has been shown to display non motor symptoms in the absence of motor
dysfunction and neuroinflammation [32], an increase in deiminated proteins was observed in the
brain vasculature, particularly in the cortex and hippocampus. Such elevated F95 positive detection
observed here correlates somewhat with a previous study on human PD post-mortem brain tissue,
although that study reported elevation of deiminated proteins in the substantia nigra [10]. In the
current rat pre-motor PD model, substantia nigra did neither show significant changes in F95 staining
(data not shown) nor in citH3 staining (Supplementary Figure S1). The increase in F95 positivity
detected in other brain areas in the current study does correlate with a previous study using cellular
iPSC neuronal models derived from fibroblasts from patients carrying α-synuclein triplication [15], in
which an increase in total deiminated proteins was observed in vitro [9].
When assessing deiminated proteins in total plasma and plasma-EVs, KEGG pathways for AD,
PD, Huntington’s disease (HD), and prion disease were found to be enriched for deiminated proteins
in the pre-motor PD model, compared with shams. Protein deimination has previously been linked
to AD [11,29–31], PD [10,12], and prion disease, including Creutzfeldt–Jakob disease (CJD) [33–35].
However, via F95-enrichment and protein–network analysis, the current study reveals for the first
time a link between protein deimination and HD, indicative of some common pathways with other
dementias, including PD, via protein deimination. Enrichment for deiminated proteins in KEGG
pathways for all these neurodegenerative diseases identified in the pre-motor PD model in this
current study therefore indicates putative common pathways for these neurodegenerative disorders,
regulated by deimination, including some contribution of deiminated protein cargo via circulating
plasma-EVs. This is in agreement with previous studies assessing KEGG pathways in AD, PD, and HD,
with the aim to identify shared pathways for distinct but related diseases that may share common
underlying pathogenic mechanisms [36]. Such identification may be of importance to further current
understanding of these neurodegenerative disorders and for the design of new treatment strategies,
especially in the early stage of the disease.
Furthermore, in the current study, KEGG pathways for “oxidative phosphorylation”, “complement
coagulation cascades”, “thermogenesis”, “metabolic pathways”, “S. aureus infection”, “gap junction”,
“platelet activation”, and “apelin signalling pathway” were only identified for F95-enriched proteins in
plasma-EVs of the pre-motor PD model, and were therefore specific to the circulating plasma-EVs in
the pre-motor PD model. The relevance of these pathways in neurodegeneration, and specifically in
relation to what is reported in the literature for PD, is further discussed below:
Oxidative phosphorylation is a vital part of metabolism, takes place in the mitochondria,
and contributes to the major source of ATP. This process also leads to the generation of reactive
oxygen species (ROS) and resulting oxidative stress and bioenergetics defects, which are linked to a
range of neurodegenerative disorders, including PD [37–39]. While oxidative stress has been shown to
play significant roles both in the onset and progression of PD [40], it still remains open to debate whether
the mitochondrial respiratory deficiencies observed in a range of neurodegenerative disorders are
initiators or consequences of prior insult [41]. Mitochondrial dysfunction has been found to be severe
in cortex and in advanced stages of PD patients, based on algorithm analysis [42]. Identification of
post-translational deimination in KEGG pathways of oxidative phosphorylation that was here identified
for the first time in the pre-motor PD rat model, may provide novel insights into EV-mediated transport
of deiminated proteins and protein deimination mediated effects on mitochondrial dysfunction via
oxidative phosphorylation pathways in the pathogenesis of neurodegenerative diseases.
The complement system is an increasingly recognised factor in neurodegenerative diseases, also
with links to PD [43–45]. Neuroinflammation can also result in the disruption of the blood–brain barrier
and therefore lead to the direct participation of the adaptive immune system [46]. While complement
mediated responses are involved in chronic inflammation, the complement system forms also part of
the innate and humoral responses and has been recently linked to non-motor PD [47]. Interestingly,
levels of the key complement components of the alternative and classical pathways, C3 and C4, were
previously reported to be lower in non-motor PD compared with healthy controls [47], while severity
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of disease has been related to C3 and factor H levels in PD and AD patients [48]. However, no studies
have discussed putative effects of post-translational modifications of these complement components in
neurodegeneration, which may be a contributing factor to altered immune and inflammatory responses
in early disease stages. The post-translational deimination of several complement components,
including C3, C4, and factor H, alongside a number of other complement components, has been
recently identified in a range of taxa [49–54]. Indeed, in the current study, C2, C3, as well as factor H and
C-type lectin were found to be deimination candidates in rat plasma, both in shams and the pre-motor
PD model, while C1q, factor B, C4, C8, C9, C4-binding protein, properdin, and collectin were only
identified as deiminated in the pre-motor PD model. This indicates differences in complement pathway
regulation via post-translational deimination in early stages of PD. As a number of arginines may
undergo post-translational deimination in all these proteins, and therefore contribute to their structural
and consequently downstream functional changes, the role for deimination of complement components
in early onset neurodegeneration will need to be further evaluated. Furthermore, the involvement of
inflammatory factors and modified inflammatory responses and their involvement with the brain–gut
axis of PD also needs consideration [55]; particularly if such factors can be identified at early stages
of disease.
Thermogenesis was identified as a deimination enriched KEGG pathway. Loss of body weight
and fat mass is one of the non-motor symptoms of Parkinson’s disease and has, amongst others, been
related to brown fat tissue meditated thermogenesis [56]. Thermogenesis is related to mitochondrial
function [57,58] and also linked to synaptic transmission and neurodegeneration [59]. Alteration in
mitochondrial complexes, restricting energy output, are related to sepsis as well as PD [57] and
implicated in other neurodegenerative disease such as AD, as well as being associated with diabetes [60].
Interestingly, thermogenesis is also linked to CNS activity in hibernating animals [61,62]. Deimination in
thermogenesis pathways has not been identified before and provides a novel insight into putative
regulation via such post-translational modifications.
Metabolic KEGG pathways were identified in this study as deiminated in plasma-EVs of pre-motor
PD rats. Mitochondria are the key regulators of cellular metabolism and their dysfunction is a hallmark of
PD pathogenesis [63]. Furthermore, PD has been linked to a range of inherited metabolic disorders [64].
The metabolic landscape of neurodegenerative diseases is therefore receiving increased attention [65]
and alterations in metabolic pathways in PD, including in early pre-motor stages in PD, have been
discussed [66]. KEGG pathways for metabolic pathways have been linked to PD development based on
microarray analysis of blood samples from PD patients and matched controls [67]. The identification
here of enrichment of deiminated proteins in KEGG metabolic pathways in EVs provides a novel angle
of post-translational regulation of such processes.
S. aureus infection KEGG pathway was identified to be enriched in deiminated proteins in
plasma-EVs of the pre-motor PD rats. S. aureus has been found to be significantly increased in the
conjunctival flora in PD patients [68]. Furthermore, α-synuclein upregulation and over-expression has
been correlated with elevated innate immune responses and been verified to display antimicrobial
peptide-like properties and antibacterial activity against S. aureus, alongside other bacteria and
fungi [69]. Interestingly, phagocytic activity and bactericidal activity of neutrophils have been shown
to be affected in early AD [70]. However, the precise involvement of protein deimination in bacterial
infection pathways and in the regulation of immune responses in PD remains to be investigated.
Deimination has previously been associated with bacterial immune evasion [71], as well as with bacterial
membrane vesicle release and antibiotic resistance, highlighting roles for PAD-mediated mechanisms
in host–pathogen interactions [6]. This may be of some interest as the brain–gut axis relationship
between the gut microflora and PD has been a topic of investigation due to gastrointestinal symptoms
being one of the earliest features of PD [72]. Roles for the gut microbiota in neuroinflammation has also
been hypothesised and assessed for other neurodegenerative diseases, including AD and amyotrophic
lateral sclerosis (ALS) [73]. Deimination of KEGG bacterial infection pathways, or in dysbacteriosis,
has not been revealed in PD or other neurodegenerative diseases in previous studies, while KEGG
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pathways for bacterial infection were recently identified to be enriched in deiminated proteins in
glioblastoma [7].
Gap junction and platelet activation were identified in this study as KEGG pathways enriched in
deiminated proteins in pre-motor PD plasma EVs. Reduced platelet activation has been described in
PD [74] and furthermore a recent study has identified gap junctions and platelet activation as KEGG
pathways in early PD [26]. Gap junctions are formed by pannexins and connexins and allow for
exchange of ions, second messengers, and small metabolites between adjacent cells [75]. Gap junctions
have critical roles in homeostasis and roles in neurodegenerative disease, including PD, have been
suggested [76–78]. Deimination in these pathways has not been reported before and may provide
novel insights into such post-translationally mediated regulation in disease and disease progression.
Apelin signalling KEGG pathway was identified to be enriched in deiminated proteins in
plasma-EVs of pre-motor PD rats only. Apelin signalling is involved in a broad range of physiological
functions and furthermore associated with pathologies that result from decreased vascularisation—for
example ischaemia, or neovascularisations events such as tumours and retinopathes [79]. Apelin is
a neuropeptide with regulatory roles of many cellular functions and involvement in a range of
physiological processes including metabolic, cardiovascular function, and regulation of body fluid
homeostasis [80,81]. Apelin expression has been described in endothelial cells and the CNS [82] and
has also been found to be involved in neuronal dysfunction related to inflammation during ageing [83].
Modulation of apelin signalling has been discussed in a range of pathologies [84] and has recently also
been associated with neurodegenerative diseases [85], including AD [86–89] and PD [90–92]. However,
specific roles in PD remain to be further investigated. Apelin signalling has been linked to autophagy
in PD, both in cellular in vitro and in vivo mouse models [90,92]. PD mouse models have shown
roles for apelin in MPTP-induced damage affecting the substantia nigra, behavioral dysfunction and
dopaminergic neurodegeneration [90]. Roles for apelin signalling in endoplasmic reticulum (ER) stress
have also been identified [91] and neuroprotective roles of apelin signalling pathways have recently
been identified in PD mouse models [93]. The current study is the first to identify apelin signalling
pathways to be associated with protein deimination, and such post-translational regulation of apelin
via deimination, as identified here in pre-motor PD model plasma-EVs, may play important roles in
the multifaceted roles of apelin signalling.
In whole plasma, KEGG pathways identified to be enriched in deiminated proteins in the pre-motor
PD model compared with plasma from sham animals were KEGG pathways for PD, AD, HD, and prion
disease, retrograde endocannabinoid signalling, SLE, and NAFLD. These are further discussed below:
Retrograde endocannabinoid signalling KEGG pathways were identified in this study to be
enriched in deiminated proteins in the pre-motor PD plasma only. The retrograde endocannabinoid
signalling system is a lipid-based neuromodulatory system with important roles in the CNS including
in physiological and neurodegenerative processes [94,95]. It has been associated to pathogenesis of
PD as well as AD and ischemia [95–97] and suggested as a therapeutic target for treatment of a range
of neurodegenerative disorders including AD, PD, HD, multiple sclerosis (MS), and ALS [98–100].
Putative roles for its regulation via post-translational deimination have not been previously identified
and therefore bring a novel angle of modulation of endocannabinoid signalling pathways in
neurodegeneration, including in early disease stages.
Systemic lupus erythematosus (SLE) KEGG pathway was identified to be enriched in deiminated
proteins in plasma of the pre-motor PD rat model. SLE is a multisystemic autoimmune disease, with
association to cerebrovascular diseases [101–103] and also with PD [104]. Furthermore, Parkinsonian
syndrome has been implicated in complicating SLE [105,106]. A population-based study assessing
association of PD with SLE found an inverse association between the two, with SLE patients displaying
a decreased risk of subsequent PD, although this study did not include early stages of PD [107].
The deimination of SLE KEGG pathway in pre-motor PD model may provide novel insights into the
previously observed interplay between SLE and PD.
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NAFLD KEGG pathways were enriched in deiminated proteins in pre-motor PD model plasma-EVs.
Interestingly, a link via mitochondrial dysfunction has been made between metabolic syndrome,
diabetes, obesity, and non-alcoholic fatty liver disease in the progression of AD, PD, and other
neurodegenerative diseases [108]. Furthermore, lipid metabolism (in particular non-alcoholic fatty
liver disease pathway) and mitochondrial dysregulation have been identified as molecular pathways
and putative biomarkers linked to PD [109]. Post-translational deimination is revealed for the first
time for NAFLD associated KEGG pathways in this study and may be of relevance for the interplay of
neurodegeneration and such comorbidities.
Recent work has assessed circulating amino acid signatures in PD patient sera, where free citrulline
was found to be lower in PD than controls [110]. Furthermore, assessment of molecular signatures in
circulating small EVs have been identified in relationship to mitochondria and systemic inflammation,
including CD9, NDUFS3, C-reactive protein (CRP), fibroblast growth factor 21, interleukin 9,
macrophage inflammatory protein 1β, and tumour necrosis factor alpha [22]. Such changes have
not been assessed in pre-motor PD animal models, and interestingly in this current study, CRP
is one of the deimination candidates identified in both sham and pre-motor PD model plasma.
Whether the deimination levels of CRP differ between sham and pre-motor PD plasma needs to be
further investigated; indeed differences in CRP deimination and between CRP forms have been recently
reported in teleost fish immunity [111] but have yet to be assessed in relation to human pathologies.
Overall, deimination signatures in EVs have yet to be assessed in relation to PD or other
neurodegenerative diseases. Other proteomic approaches, including Raman profiling of circulating
EVs, have been used to elucidate putative links to PD progression and treatment [21]. Furthermore,
proteomic analysis of serum EVs in PD patients have revealed the expression levels of seven proteins,
including pigmented epithelium-derived factor, afamin, apolipoprotein D and J, are significantly
increased in PD patients. Moreover, expression levels of complement C1q and protein immunoglobulins,
have been reported to be decreased in PD patients [112]. Some of these proteins including C1q,
immunoglobulins, and apolipoprotein A, B, and E (but not D and J) were identified to be deiminated
in the pre-motor PD model, bringing a novel aspect of post-translationally mediated regulation and
modification of protein function, possibly contributing to disease mechanisms. A recent study using
a cellular model of PD, treated with MPP+, a well-established parkinsonian toxicant, reported that
microglial EVs, when not stimulated by aggregated α-synuclein, appeared to be protective, possibly
involving mitochondrial dynamics and mitochondrial fission [113]. Furthermore, deimination of
Nicotinamide- N-methyltransferase (NNMT), which is implicated in several chronic diseases as well
as PD, has recently been identified [114]. These previous findings, as well as our present data, further
support roles for EVs and circulating deiminated proteins, including in plasma-EVs, in the involvement
of PD, including in early pre-motor stages, as identified in the current study.
In the present study, the brain tissue of pre-motor PD rats showed significant increase in total
deiminated proteins, as assessed by the pan-deimination F95 antibody and for deiminated histone H3.
While PAD2, PAD3, and PAD4 protein expression was confirmed in the rat brains, including in the
cortex, hippocampus, and white matter, there was no significant difference in PAD isozyme protein
levels, although some elevated levels were noted for PAD4 and to a lesser level for PAD3 protein
in the pre-motor PD brains. Their deiminated protein products showed though a significant and
marked increase in the pre-motor PD brains, particularly in the cortex, white matter, and hippocampus,
while deiminated histone H3 was increased in the dentate gyrus as well as in the cortex. As protein
deimination is a result of PAD activation, increased levels of PAD proteins per se would not necessarily
be expected at this stage, while an increased production of deiminated protein products would
be the result of PAD activation, leading to increased production of deiminated protein products.
As dysregulation of calcium homeostasis is a known contributor to a number of neurodegenerative
diseases, including in PD [115,116], and PADs are calcium activated enzymes, an increase in protein
deimination would be one of such downstream factors. In previous studies on post-mortem PD
brain samples, increased levels of total protein deimination and deimination-positive extracellular
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plaques have indeed been reported [10]. Furthermore, the presence of mutated misfolded α-synuclein
protein has also been related to increased protein deimination [12]. Supporting those post-mortem
studies, in vitro studies using iPSC derived neuronal models carrying α-synuclein triplication, revealed
increased protein deimination levels, although specific target proteins of deimination were not further
assessed [9].
A hitherto unrecognised contribution of deiminated proteins to the inflammatory responses,
which previously have been shown in the pre-motor PD rat model [32], has to also be considered via
the release of deiminated neuronal proteins from necrotic neurons, as well as via the circulation of
deiminated proteins in the cerebrospinal fluid, which can contribute to progressive pathology due
to generation of autoantibodies [117]. Furthermore, the significant increase observed in F95-positive
brain vasculature of the pre-motor PD model, in particular in the cortex and hippocampus, and to some
extent in the white matter, may also affect both local and systemic EV release and contribute to the
spread and progression of pathology. Deiminated proteins also expose neo-epitopes which, in addition
to leakage of deiminated proteins from dying cells, can further contribute to neuro-inflammatory
responses. This also includes histone deimination which, in addition to gene regulatory effects, may
cause extracellular trap formation which can contribute to local tissue damage [118]. Increased levels
of deiminated histone H3 were here observed in the dentate gyrus as well as in cortex of the pre-motor
PD brains. Such increase in citH3 positive detection may be of considerable importance in the
neuroinflammatory environment; indeed, previous studies of CNS injury, including via hypoxic
damage, have shown that pharmacological inhibition of PADs, and associated reduction of citH3,
correlates with neuroprotective effects [119–121].
Recent work has emphasised the association of selected microRNAs to PD [27,122,123] and roles for
microRNAs in neuroinflammation have received increased attention [25,124]. As neuroinflammation
is thought to be a facilitator of PD pathogenesis, and was observed in the pre-motor PD model used
in this study [32,125], we assessed changes in relative expression levels of three inflammatory and
hypoxia associated microRNAs: miR21, miR155, and miR210. These microRNAs have previously been
related to neurodegenerative diseases, including PD, although none of these microRNA (miRs) have
been assessed, or associated with, pre-motor PD before the current study. All the microRNAs were here
found to be significantly increased in circulating plasma-EVs of the pre-motor PD model. Known roles
for these microRNAs in relation to neurodegeneration, including PD, are discussed below:
miR21 is a key regulator of inflammation [126], also associated with oxidative stress [127] and
involved in neuroinflammatory regulation [128–130]. miR21 has been found to be upregulated in
multiple sclerosis (MS), although specific functions have not been identified [131]. In PD, miR21
has been associated to autophagy [132]. Moreover, miR21 has been identified as a biomarker in
plasma/serum for AD, prion disease, as well as traumatic brain injury [24,124,133,134], where it has
also been found to be increased in EVs [135]. The current study is the first one to identify elevated
miR21 as a marker of pre-motor PD.
miR155 has previously been identified as a contributor to the induction of
neuroinflammation [25,136] and to increase blood–brain barrier (BBB) permeability [137]. In PD,
miR155 has been linked to microglial inflammatory response induced by α-synuclein [23]. It has
also been associated with various other neuroinflammatory disorders including MS, where it has
been identified as a biomarker [138]. mir155 is also found to be elevated in AD and to contribute to
neuroninflammation in this disease [139] and identified as a biomarker [124,133]. In PD, miR155 has
been implicated in mitochondrial regulation in dopaminergic cell death in later stage [140], however
this study presents a link between miR155 and pre-motor PD for the first time.
miR210 is a hypoxia-related microRNA, also linked to inflammation, and is induced under hypoxic
conditions. It plays key roles in mitochondrial metabolism, apoptosis, cell proliferation, and the
DNA damage response [141–144]. miR210 has been associated with mitochondrial dysfunction and
oxidative stress in relation to neurodegenerative diseases [145,146]. It has previously been linked to
PD in cell culture models, assessing environmental neurotoxicant mangane, in which miR210 was
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identified in EVs [147]. The interplay between oxidative stress and microRNAs has been shown in a
number of neurodegenerative diseases including AD, PD, HD, and ALS [148]. Oxidative stress has
indeed been suggested to play key roles in PD, although some parameters from clinical studies have
been inconsistent [149]. Therefore, the identification in the current study of miR210 being significantly
elevated in the pre-motor PD model indicates a hitherto unrecognized contribution by EV-mediated
transport of this microRNA in early stages of PD.
Modifications of EV-mediated export of misfolded proteins, DNA, RNA, miRNAs, enzymes,
and other EV cargo may be of considerable importance already in early stages of PD, and in
neurodegenerative disease progression, and contribute to pathology. The transport of EV transcytosis
across the BBB and associated release of EV cargo from brain endothelial cells into the systemic
circulation has for example been suggested [150]. This correlates with strongly F95-positive vasculature
observed in the pre-motor PD brains in the current study, which could also contribute to increased EV
release from these sites. Therefore, the identification of early changes, such as EV numbers released
and associated changes in specific EV microRNA and deiminated protein cargo, as identified here in
circulating EVs in the rat pre-motor PD model, may offer novel markers indicative of early stages of
pre-motor PD and be developed into useable screening tools.
4. Materials and Methods
4.1. Induction of the Rat Model of Pre-Motor PD
All procedures were approved by the Bloomsbury ethical committee and the Home Office and
followed the British Home Office regulations with regard to the Animal Scientific Procedures Act
1986 (PPL PP3144142). Male Sprague-Dawley rats (200–250 g—Charles River Laboratories, U.K.)
were kept under constant conditions of humidity (40–60%), temperature (18–22 ◦C), and a 12 h
light–dark cycle. The induction of the pre-motor model was carried out as previously described [32].
In brief, intraperitoneal administration of either N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4,
Sigma-Aldrich; a noradrenergic neurotoxin- pre-motor model) at a dose of 25 mg/kg, or sterile saline
(sham animals) was performed 4 days prior to dopaminergic neurotoxin insult with 6-hydroxydopamine
(6-OHDA). Bilateral striatal injections of either 6-OHDA (Sigma-Aldrich—dissolved in saline solution
containing 0.9% ascorbic acid- pre-motor model) or saline containing 0.9% ascorbic acid for sham
animals were then performed using the following coordinates from the atlas of Paxinos and Watson
(1982), from Bregma: AP +1.0 mm, ML +3.0 mm, DV −6.5 mm. Animals were anaesthetised using
isoflurane (5% v/v in O2 for induction and 2% v/v in O2 for maintenance) delivered through a fitted
nose mask and rats were secured to a stereotaxic frame using blunt ear bars (David Kopf Instruments,
Bethesda, MD, USA). Each animal received 15 µg of 6-OHDA per striatum (or vehicle) at a flow rate
of 1 µL/min-1. Daily monitoring of the animals was performed following the surgical procedures.
Rats were divided into two experimental groups: sham-treated animals (n = 3) and toxin-treated model
(pre-motor model—n = 3). This pre-motor PD model was shown to present non-motor symptoms in
the absence of motor dysfunction in a previous study [32]. The pre-motor PD models did not present
any motor dysfunction prior to culling.
4.2. Immunohistochemistry
All histological procedures have been previously described [32,151]. Sham animals and pre-motor
PD models were anaesthetised by inhalation of isoflurane and intraperitoneal injection of Euthatal
(Merial, Harlow, UK) (60 mg/kg) and perfused transcardiacally with ice-cold oxygenated artificial
cerebrospinal fluid (ACSF) containing in mM: 124 NaCl, 25.5 NaHCO3, 3.3 KCl, 1.2 KH2PO4, 1 MgSO4,
2.5 CaCl2, 15 mM D-Glucose equilibrated with 95% O2/5% CO2. Brains were removed and fixed
overnight (4% paraformaldehyde, 0.2% saturated picric acid solution, 0.025% glutaraldehyde solution
in 0.1 M Phosphate buffer). Fifty micrometers coronal sections containing cortex and hippocampus
were cut with a vibratome (Agar Scientific Ltd, Stansted, UK). One in eight sections were collected
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and 4–5 slices per animal were used per staining. Sections were incubated first in 1% H2O2 for
30 min and then in 1% sodium borohydride (NaBH4) for 30 min to decrease background staining
and then blocked in 10% normal goat serum (NGS) for another 30 min to block non-specific antibody
binding. Sections were incubated overnight at 4 ◦C in the respective primary antibodies diluted in
Phosphate Buffer Saline (PBS) containing 0.5% Triton X-100 (Sigma-Aldrich, Haverhill, UK): Mouse
anti-peptidyl-citrulline F95 (for total deiminated proteins, MABN328, Merck, diluted 1:200), rabbit
anti-Histone H3 (citrulline R2 + R8 + R17, ab5103, Abcam, diluted 1:200), rabbit anti-PAD2 (ab50257,
Abcam; diluted 1:200), rabbit anti-PAD3 (ab50246; diluted 1:200) and rabbit anti-PAD4 (ab50332;
diluted 1:200). Biotinylated labelled secondary anti-mouse IgM (Vector Laboratories—diluted 1:100)
or anti-rabbit IgG (Diluted 1:500—Vector laboratories) were applied for 6 h. Sections were then
washed and incubated in ABC (Vector Laboratories) overnight, washed, and then incubated in 3,
3′ diaminobenzidine (DAB- Sigma Aldrich) for 20 min. H2O2 was added to the DAB solution to
allow the reaction until the filled cells were sufficiently labelled. Sections from the two groups were
processed together and the DAB reaction was stopped at the same time to allow comparison between
the shams and pre-motor models. Sections were placed onto Superfrost slides, dehydrated, cleared
with Histoclear, and mounted using DPX (Sigma Aldrich). Levels of F95 immunohistochemical staining
were measured by quantitative thresholding image analysis as previously described (Rahim et al.,
2012; Sancandi et al., 2018). Images of both cortex and hippocampal CA1 in each section were captured
using a DMR microscope and Leica Application Suite V4 (Leica Microsystems, Wetzlar, Germany)
at 5×magnification with constant light intensity, microscope calibration, and video camera settings.
Images were analysed using Image-Pro Premier (Media Cybernetics, Cambridge, UK) by measuring
immunoreactivity using a constant threshold that was applied to all images for each respective antigen.
Data are presented as the mean percentage area of immunoreactivity ± SEM.
4.3. EV isolation and Quantification by Nanoparticle Tracking Analysis
Plasma was isolated from blood collected from the heart of the anaesthetized rats via cardiac
puncture prior to perfusion (described above). Two aliquots of 1.5 mL of blood were collected from
each animal and plasma was isolated by centrifugation at 2000 g for 10 min, immediately aliquoted and
frozen at −80 ◦C. EV isolation was carried out according to previously established protocols [5,7,54] as
well as the recommendations of the International Society of Extracellular Vesicle Research (ISEV) [152].
Plasma aliquots were thawed before EV isolation and differential centrifugation was carried out by
adding 100 µL plasma to 400 µL Dulbecco’s PBS (DPBS) and centrifuged at 4000 g for 30 min at 4 ◦C
for removal of aggregates and apoptotic bodies. Next, centrifugation of the collected supernatant
was carried out for 1 h at 4 ◦C at 100,000 g. The supernatant was then discarded and the isolated EV
pellets were resuspended in ice-cold DPBS and centrifuged again at 100,000 g for 1 h at 4 ◦C. Thereafter,
the final EV enriched pellet was resuspended in 100 µL sterile EV-free PBS. Nanoparticle tracking
analysis (NTA) was carried out to quantify the EVs, using the NS300 Nanosight (Malvern Panalytical
Ltd, Malvern, UK), equipped with a sCMOS camera and a 405 nm diode laser. EV samples were
diluted 1:100 in sterile-filtered EV-free DPBS before application to the Nanosight. Particle numbers in
the field of view were maintained within the rage of 40–60. The camera settings were set according
to the manufacturer’s instructions (Malvern) at level 10 for recording of five 60 s videos per sample.
For post-analysis of the recorded videos, the detection threshold was set at 5 and the obtained replicate
histograms were averaged for each sample.
4.4. Western Blotting Analysis for EV Characterisation
For western blotting analysis, the plasma-EVs were re-constituted in 2 × Laemmli sample
buffer containing 5% β-mercaptoethanol (BioRad, Kidlington, UK) and heated for 5 min at 100 ◦C.
The proteins were separated on 4–20% Mini-Protean TGX protein gels (BioRad) by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by semi-dry western blotting.
Ponceau S staining (Sigma, U.K.) was used to assess even transfer to nitrocellulose membranes (0.45 µm,
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BioRad), which were thereafter blocked for 1 h at room temperature (RT) in 5% bovine serum albumin
(BSA) (Sigma) in Tris buffered saline (TBS) containing 0.1% Tween20 (TBS-T). Primary antibody
incubation was carried out overnight at 4 ◦C using antibodies for two EV-specific markers: CD63
(ab68418; Abcam, Cambridge, UK; diluted 1:1000 in TBS-T) and Flotillin-1 (Flot-1; ab41927; Abcam;
diluted 1:2000 in TBS-T). Thereafter, membranes were washed in TBS-T and incubated at RT for
1 h with HRP-conjugated anti-rabbit IgG secondary antibodies (BioRad, diluted 1:3000 in TBS-T).
The membranes were washed for five times 10 min in TBS-T, followed by a final wash in TBS without
Tween20. Protein bands were visualised using enhanced chemiluminescence (ECL; Amersham, U.K.)
and the UVP BioDoc-ITTM System (Thermo Fischer Scientific, Hemel Hempstead, UK).
4.5. EV Characterisation by Transmission Electron Microscopy
TEM imaging of EVs was carried out according to previously described protocols [7,53].
The plasma-EVs were resuspended in 100 mM sodium cacodylate buffer (pH 7.4). One drop (~3–5 µL)
of the EV suspension was placed onto a grid carrying a carbon support film, which previously had been
glow discharged. After the suspension had partly dried, the grid was placed on to a drop of a 2.5%
glutaraldehyde solution in 100 mM sodium cacodylate buffer (pH 7.4) for 1 min and thereafter washed
by touching it to the surface of three drops of distilled water. Excess water was carefully removed
using a filter paper. A drop of 2% aqueous Uranyl Acetate stain (Sigma-Aldrich) was next applied to
the grid. Following 1 min, any excess stain was removed using a filter paper. The grid was dried at
room temperature, whereafter the samples were imaged in TEM using a JEOL JEM 1400 transmission
electron microscope (JEOL, Tokyo, Japan), which was operated at 80 kV at a magnification of 30,000 to
60,000. Digital images of EVs were recorded with an AMT XR60 CCD camera (Deben UK Limited,
Bury Saint Edmunds, UK).
4.6. Analysis of microRNAs miR21, miR155, and miR210 in Plasma-EVs
For assessment of microRNA cargo in plasma-derived EVs of the pre-motor PD models and
sham treated rats, EVs were isolated as described above and further processed for RNA isolation,
cDNA translation, and assessment for expression of miR21, miR155, and miR210, according
to previously described protocols [7]. First, RNA was extracted using Trizol (Sigma Aldrich,
Gillingham, UK) and thereafter the RNA concentration and purity were measured by NanoDrop
Spectrophotometer at 260 nm and 280 nm absorbance. The RNA was then reverse transcribed to
cDNA, using the qScript microRNA cDNA Synthesis Kit (Quantabio, Beverly, MA, USA), following
the manufacturer’s instructions. The resulting cDNA was utilised for assessment of relative expression
levels of miR21, miR155, and miR210. Reference RNAs used for normalisation of miR expressions
were U6 and hsa-let-7a-5p. MystiCq microRNA qPCR primers for miR21 (hsa-miR-21-5p), mir155
(hsa-miR-155-5p), and miR210 (hsa-miR-210-5p), all obtained from Sigma (U.K.), were used together
with the PerfeCTa SYBR® Green SuperMix (Quantabio). The sequences for U6-snRNA primers
were as follows: U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and hsa-let-7a-5p forward
5′-CCGAGCTGAGGTAGTAGGTTGTATA-3′ reverse 5′-CGCTTCACGAATTTGCGTGTCAT-3′ for
both. The following thermocycling conditions were applied: Denaturation: 95 ◦C for 2 min; followed by
40 cycles at 95 ◦C for 2 s and 60 ◦C for 15 s; extension was carried out at 72◦ C for 15 s. Expression levels
of miR21, miR155, and miR210 were thereafter normalized to that of U6, according to the 2∆∆CT
method [153]. Each experiment was repeated in biological and technical triplicates.
4.7. Assessment of KEGG Pathways for Deiminated Proteins in Plasma and Plasma-EVs
F95 enrichment of deiminated proteins was carried out according to previously described
protocols [7,53,54]. Rat plasma (a pool of 3 × 30 µL, using 30 µL aliquots from 3 individual animals per
experimental group) and plasma-EVs (a pool of 3 × 30 µL extracted EVs from 3 individual animals
per experimental group) respectively, were added to mini-prep sepharose columns in the presence of
the pan-deimination F95 antibody (MABN328, Merck, Feltham, UK; [154]) for immunoprecipitation
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of total deiminated proteins, using the Catch and Release® v2.0 Immunoprecipitation Kit according
to the manufacturer’s instructions (Merck). F95-enrichment was carried out overnight at 4 ◦C on a
rotating platform and the F95 bound proteins were thereafter eluted using denaturing elution buffer,
according to the manufacturer’s instructions (Merck). F95-enriched eluates from the plasma and
plasma-EVs were thereafter analysed both by SDS-PAGE electrophoresis followed by silver staining as
well as by liquid chromatography with tandem mass spectrometry (LC-MS/MS; Cambridge Proteomics,
Cambridge, UK), according to previously described methods [7,53]. For LC-MS/MS, the F95-enriched
eluates were first run 0.5 cm into a 12% TGX gel (BioRad) and thereafter cut out as one band each,
respectively. The 1D gel bands were then transferred into a 96-well PCR plate. The gel-bands were cut
into 1 mm2 pieces, destained, reduced using DTT, and alkylated using iodoacetamide, and thereafter
digested with trypsin overnight at 37 ◦C. Thereafter, the supernatant was pipetted into a sample vial,
following by loading onto an autosampler for automated LC-MS/MS analysis using a Dionex Ultimate
3000 RSLC nanoUPLC (Thermo Fisher Scientific Inc., Waltham, MA, USA) system in conjunction
with a QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Peptide separation was carried out using reverse-phase chromatography (flow rate 300 nL/min) and
a Thermo Scientific reverse-phase nano Easy-spray column (Thermo Scientific PepMap C18, 100A
pore size, 2 µm particle size, 75 µm i.d. ×50 cm length). The peptides were loaded onto a pre-column
(Thermo Scientific PepMap 100 C18, 5 µm particle size, 100A pore size, 300 µm i.d. ×5 mm length)
from the Ultimate 3000 autosampler together with 0.1% formic acid for 3 min (flow rate 10 µL/min).
Thereafter, the column valve was switched for elution of peptides from the pre-column onto the
analytical column. Solvent A was water containing 0.1% formic acid, while solvent B contained 20%
water and 80% acetonitrile, as well as 0.1% formic acid. A linear gradient of 2–40% B was employed
for 30 min. The LC eluent was sprayed into the mass spectrometer using an Easy-Spray source
(Thermo Fisher Scientific Inc.). The m/z values of all eluting ions were measured in an Orbitrap mass
analyzer, which was set at a resolution of 70,000, while scanning was performed between m/z 380–1500.
Data dependent scans (selecting top 20) were employed for automatic isolation and generation of
fragment ions by higher energy collisional dissociation (HCD, NCE:25%) using the HCD collision
cell. The resulting fragment ions were measured using the Orbitrap analyser, which was set at a
resolution of 17,500. Both singly charged ions as well as ions with unassigned charge states were
excluded from selection for MS/MS. A dynamic exclusion window of 20 sec was also applied. The data
was processed post-run using Protein Discoverer (version 2.1., Thermo Scientific). In brief, MS/MS
data was converted to mgf files which were submitted Mascot (Mascot search algorithm; Matrix
Science, London, UK). Search for hits was carried out against the UniProt Rattus_norvegicus_20181203
(31,558 sequences; 17,280,660 residues) database as well as common contaminant sequences database
(123 sequences; 40,594 residues). Peptide and fragment mass tolerances were respectively set at 20 ppm
and 0.1 Da. The threshold value for significance was set at p < 0.05, while the peptide cut-off score
was set at 20. To identify protein–protein interaction networks for deiminated proteins identified
in whole plasma and plasma-EVs, respectively, STRING analysis (Search Tool for the Retrieval of
Interacting Genes/Proteins; https://string-db.org/) was used. The protein networks were built as follows:
function applied in STRING was “search multiple proteins”, the species database chosen was “Rattus
norvegicus”, and “basic settings and medium confidence were applied. Colour lines between the nodes
indicate the following evidence-based interactions for network edges: “known interactions” (these are
based on curated databases, experimentally determined), as well as “predicted interactions” (these are
based on gene neighbourhood, gene fusion, gene co-occurrence, or via text mining, co-expression, or
protein homology).
4.8. Silver Staining
Following electrophoresis under reducing conditions as described above, using SDS-PAGE 4–20%
TGX gels (BioRad), the F95-enriched eluted proteins from rat plasma and plasma-EVs were stained by
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silver staining. Staining was carried out using the BioRad Silver Stain Plus Kit (1610449, BioRad, UK),
according to the manufacturer’s instructions (BioRad).
4.9. Statistical Analysis
All graphs were prepared and statistical analysis was performed using GraphPad Prism version 7
(GraphPad Software, San Diego, CA, USA). The experiments were repeated in triplicates, all histograms
represent mean of data, while the error bars indicate standard deviation (SD). Significant differences
were considered as p ≤ 0.05, following Student’s t-test. The NTA curves were generated by the
NanoSight 3.0 software (Malvern, UK) with the black line representing the mean of the 5 repetitive
readings per sample and the red line representing standard error (+/−).
5. Conclusions
In summary, the findings of the current study highlight PAD-mediated communication in early
pre-motor stages of PD, both with respect to cerebrovascular changes as well as post-translational
changes in protein networks relating to neurodegenerative diseases in plasma and EV-cargo. Changes of
EV-mediated microRNA export were also verified, with increased expression of inflammatory and
hypoxia related microRNAs in circulating plasma-EVs in the pre-motor PD model. Overall, an increase
in F95 positive proteins, both in brain tissue and plasma, as well as in circulating plasma-EVs observed
here in the pre-motor PD model, highlights hitherto under-recognized roles for these parameters in
early stages of PD. Our findings emphasise the need to further assess and refine protein deimination
and EV related microRNA and deimination biomarkers for early pre-motor PD diagnosis.
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no positive immunodetection for citH3. A similar result was seen for F95 which also showed negative in SN both
in sham and pre-motor PD brains (not shown); the scale-bar represents 100 µm.
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